A Study of Liposomal Bupivacaine Versus 0.25% Bupivacaine Hydrochloride Post Breast Reduction

Description

The purpose of this research is to assess pain scores and opioid use when using Liposomal (Exparel) Bupivacaine versus Bupivacaine Hydrochloride.

Conditions

Breast Reduction

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this research is to assess pain scores and opioid use when using Liposomal (Exparel) Bupivacaine versus Bupivacaine Hydrochloride.

Liposomal Bupivacaine Versus 0.25% Bupivacaine Hydrochloride for Postoperative Analgesia After Breast Reduction Surgery: A Prospective, Single Blind, Non-randomized Controlled Trial

A Study of Liposomal Bupivacaine Versus 0.25% Bupivacaine Hydrochloride Post Breast Reduction

Condition
Breast Reduction
Intervention / Treatment

-

Contacts and Locations

Rochester

Mayo Clinic Minnesota, Rochester, Minnesota, United States, 55905

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    18 Years to 70 Years

    Sexes Eligible for Study

    FEMALE

    Accepts Healthy Volunteers

    Yes

    Collaborators and Investigators

    Mayo Clinic,

    Basel Sharaf, MD, DDS, PRINCIPAL_INVESTIGATOR, Mayo Clinic

    Study Record Dates

    2024-12